Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3

Cell Reports

Volumn 7, Issue 1, 2014, Pages 86-93

  Sun, Chong ^a   Hobor, Sebastijan ^b   Bertotti, Andrea ^b,c   Zecchin, Davide ^b,c   Huang, Sidong ^a,d   Galimi, Francesco ^b,c   Cottino, Francesca ^b   Prahallad, Anirudh ^a   Grernrum, Wipawadee ^a   Tzani, Anna ^a   Schlicker, Andreas ^a   Wessels, Lodewyk F A ^a   Smit, Egbert F ^e   Thunnissen, Erik ^e   Halonen, Pasi ^a   Lieftink, Cor ^a   Beijersbergen, Roderick L ^a   DiNicolantonio, Federica ^c   Bardelli, Alberto ^b,c,f   Trusolino, Livio ^b,c   Bernards, Rene ^a   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d MCGILL UNIVERSITY   (Canada)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; AZD 624; BIM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN BAD; SELUMETINIB; TRAMETINIB; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB3 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; RAS PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COLONIC NEOPLASMS; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE KINASES; MICE; MICE, NUDE; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898023140     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.02.045     Document Type: Article

References (29)

1. Abel E.V., Basile K.J., Kugel C.H., Witkiewicz A.K., Le K., Amaravadi R.K., Karakousis G.C., Xu X., Xu W., Schuchter L.M., et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J.Clin. Invest. 2013, 123:2155-2168.
2. Adjei A.A., Cohen R.B., Franklin W., Morris C., Wilson D., Molina J.R., Hanson L.J., Gore L., Chow L., Leong S., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J.Clin. Oncol. 2008, 26:2139-2146.
3. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
4. Bernards R. A missing link in genotype-directed cancer therapy. Cell 2012, 151:465-468.
5. Bonni A., Brunet A., West A.E., Datta S.R., Takasu M.A., Greenberg M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999, 286:1358-1362.
6. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 1989, 49:4682-4689.
7. Corcoran R.B., Cheng K.A., Hata A.N., Faber A.C., Ebi H., Coffee E.M., Greninger P., Brown R.D., Godfrey J.T., Cohoon T.J., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
8. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
9. Ebi H., Corcoran R.B., Singh A., Chen Z., Song Y., Lifshits E., Ryan D.P., Meyerhardt J.A., Benes C., Settleman J., et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J.Clin. Invest. 2011, 121:4311-4321.
10. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N.Engl. J. Med. 2010, 363:809-819.
11. Flaherty K.T., Infante J.R., Daud A., Gonzalez R., Kefford R.F., Sosman J., Hamid O., Schuchter L., Cebon J., Ibrahim N., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N.Engl. J. Med. 2012, 367:1694-1703.
12. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
13. Harada H., Quearry B., Ruiz-Vela A., Korsmeyer S.J. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc. Natl. Acad. Sci. USA 2004, 101:15313-15317.
14. Jänne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., Franke F.A., Grinsted L., Zazulina V., Smith P., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013, 14:38-47.
15. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Jänne P.A., Costa D.B., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N.Engl. J. Med. 2010, 363:1693-1703.
16. Lehár J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., Rickles R.J., Short G.F., Staunton J.E., Jin X., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 2009, 27:659-666.
17. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N.Engl. J. Med. 2004, 350:2129-2139.
18. Migliardi G., Sassi F., Torti D., Galimi F., Zanella E.R., Buscarino M., Ribero D., Muratore A., Massucco P., Pisacane A., et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin. Cancer Res. 2012, 18:2515-2525.
19. Montero-Conde C., Ruiz-Llorente S., Dominguez J.M., Knauf J.A., Viale A., Sherman E.J., Ryder M., Ghossein R.A., Rosen N., Fagin J.A. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Cancer Discov. 2013, 3:520-533.
20. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
21. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nature reviews 2011, 11:761-774.
22. Scheid M.P., Schubert K.M., Duronio V. Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J.Biol. Chem. 1999, 274:31108-31113.
23. Sears R., Leone G., DeGregori J., Nevins J.R. Ras enhances Myc protein stability. Mol. Cell 1999, 3:169-179.
24. Sears R., Nuckolls F., Haura E., Taya Y., Tamai K., Nevins J.R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000, 14:2501-2514.
25. Sithanandam G., Anderson L.M. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008, 15:413-448.
26. Suen T.C., Hung M.C. c-myc reverses neu-induced transformed morphology by transcriptional repression. Mol. Cell. Biol. 1991, 11:354-362.
27. Wang J., Kim J., Roh M., Franco O.E., Hayward S.W., Wills M.L., Abdulkadir S.A. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 2010, 29:2477-2487.
28. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
29. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996, 87:619-628.